Semaglutide (GLP-1 Analogue)

This guide summarizes the dosing and cycling information shown for Semaglutide. Dosing is described as a once-weekly protocol with gradual titration based on response and goal.

Dosing & Titration (As Listed):
• 250 mcg – 2400 mcg per dose
• Increase by 250 mcg every 4 weeks until goal response is achieved
• More is not always better

Cycling (As Listed):
• 1× weekly, run as 3-month cycles with a minimum 1 month off
• Cycles may be extended depending on response and goal

Caution & Contraindications:
Caution:
• Use caution in individuals with hypoglycemia (low blood sugar), pancreatic conditions, kidney conditions, and/or gastrointestinal conditions
• May cause nausea, diarrhea, and stomach discomfort
Contraindications:
• Individuals with type 1 diabetes and/or severe kidney impairment
• Pregnant individuals

Reconstitution Options (Vial Format):
• 3 mg
• 5 mg
• 6 mg
• 10 mg
• 15 mg

Reconstitution (General Handling):
• Use sterile technique and sanitize the vial stopper before access.
• Add diluent slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (avoid vigorous shaking).
• Store refrigerated at 2–8 °C, protected from light as applicable, and follow vendor label/spec guidance.

Sequence: HXEGTFTSDVSSYLEGQAAK-OH.steric diacid-EFIAWLVRGRG

Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉

Molecular Weight: 4113.64 g/mol

PubChem CID: 56843331

CAS Number: 910463-68-2

Synonyms: Semaglutide, Oxempic, Rybelsus, NN9535

incretin effect.

A GLP-1 receptor has been identified on pancreatic beta cells, indicating that GLP-1 directly triggers the release of insulin from the pancreas. When combined with sulfonylurea drugs, GLP-1 can enhance insulin secretion, leading to mild hypoglycemia in up to 40% of individuals. Increased insulin secretion has various positive effects, including promoting protein synthesis, reducing protein breakdown, and enhancing amino acid uptake by skeletal muscles.

GLP-1 and Beta Cell Protection Research conducted in animal models suggests that GLP-1 can stimulate the growth and proliferation of pancreatic beta cells. It may also encourage the differentiation of new beta cells from progenitor cells in the pancreatic duct epithelium. Additionally, GLP-1 has been shown to inhibit beta cell apoptosis. Cumulatively, these effects shift the balance of beta cell growth and death toward growth, suggesting that GLP-1 may have potential therapeutic value in treating diabetes and protecting the pancreas from damage that could harm beta cells.

GLP-1 and Appetite Studies conducted in mouse models indicate that administering GLP-1, along with its counterpart GLP-1, directly into the brains of mice can reduce the urge to eat and suppress food intake. It appears that GLP-1 may enhance feelings of fullness, indirectly reducing hunger. Recent clinical studies in mice have shown that twice-daily administration of GLP-1 receptor agonists leads to gradual and consistent weight loss. Over time, this weight loss is associated with significant improvements in cardiovascular risk factors and a reduction in hemoglobin A1C levels, which is a marker for diabetes severity and blood sugar control.

GLP-1 is associated with minimal to moderate side effects, excellent subcutaneous bioavailability in mice, and low oral bioavailability. It's important to note that dosage per kilogram in mice does not directly correlate to human dosages. GLP-1 is available for research purposes only and should not be consumed by humans without the appropriate research licensing.

PubMed

Article Author:

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Case Western Reserve University School of Medicine

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as 'in glass' studies, are conducted outside of living organisms. It's important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.